CO2022015048A2 - Métodos y composiciones para tratar o prevenir una afección inflamatoria - Google Patents

Métodos y composiciones para tratar o prevenir una afección inflamatoria

Info

Publication number
CO2022015048A2
CO2022015048A2 CONC2022/0015048A CO2022015048A CO2022015048A2 CO 2022015048 A2 CO2022015048 A2 CO 2022015048A2 CO 2022015048 A CO2022015048 A CO 2022015048A CO 2022015048 A2 CO2022015048 A2 CO 2022015048A2
Authority
CO
Colombia
Prior art keywords
methods
compositions
inflammatory condition
inflammatory
treating
Prior art date
Application number
CONC2022/0015048A
Other languages
English (en)
Spanish (es)
Inventor
Sudhanshu Agarwal
Mark Robert Bleackley
Joel Bradley Latham
Original Assignee
Incannex Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020901030A external-priority patent/AU2020901030A0/en
Application filed by Incannex Healthcare Ltd filed Critical Incannex Healthcare Ltd
Publication of CO2022015048A2 publication Critical patent/CO2022015048A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CONC2022/0015048A 2020-04-02 2022-10-21 Métodos y composiciones para tratar o prevenir una afección inflamatoria CO2022015048A2 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AU2020901030A AU2020901030A0 (en) 2020-04-02 A method of treatment
AU2020902432A AU2020902432A0 (en) 2020-07-14 A method of treatment
AU2020903985A AU2020903985A0 (en) 2020-11-02 A method of treatment
AU2020904264A AU2020904264A0 (en) 2020-11-18 A method of treatment
AU2021900241A AU2021900241A0 (en) 2021-02-03 A method of treatment
AU2021900324A AU2021900324A0 (en) 2021-02-10 A method of treatment
PCT/AU2021/050226 WO2021195691A1 (en) 2020-04-02 2021-03-15 Methods and compositions for treating or preventing an inflammatory condition

Publications (1)

Publication Number Publication Date
CO2022015048A2 true CO2022015048A2 (es) 2022-11-08

Family

ID=77926837

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0015048A CO2022015048A2 (es) 2020-04-02 2022-10-21 Métodos y composiciones para tratar o prevenir una afección inflamatoria

Country Status (8)

Country Link
US (1) US20230128114A1 (enExample)
EP (1) EP4125835A4 (enExample)
JP (1) JP2023521634A (enExample)
AU (1) AU2021250462A1 (enExample)
CA (1) CA3169702A1 (enExample)
CO (1) CO2022015048A2 (enExample)
IL (1) IL296943A (enExample)
WO (1) WO2021195691A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023283684A1 (en) * 2021-07-15 2023-01-19 Incannex Healthcare Limited Composition comprising cannabidiol and hydroxychloroquine in a fixed dose combination capsule
WO2024025525A1 (en) * 2022-07-27 2024-02-01 Medterra Pharma Llc Cannabinoid compositions and methods of using for the treatment of non-eosinophilic inflammation and inflammatory disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453431A (en) * 1993-10-29 1995-09-26 Gilman; Andrew L. Use of hydroxychloroquine for treatment of graft-versus-host disease
GB9807639D0 (en) * 1998-04-14 1998-06-10 Kennedy Rheumatology Inst Anti-inflammatory agents
US20040242632A1 (en) * 2001-11-09 2004-12-02 Charous B. Lauren Method for treating inflammatory bowel disease
US20200009078A1 (en) * 2018-07-03 2020-01-09 TRUETIVA, Inc. Oral compositions
CN115916336A (zh) * 2020-02-19 2023-04-04 施里玛·麦钱特 大麻二酚的组合物和治疗用途

Also Published As

Publication number Publication date
AU2021250462A1 (en) 2022-12-01
IL296943A (en) 2022-12-01
CA3169702A1 (en) 2021-10-07
WO2021195691A1 (en) 2021-10-07
EP4125835A4 (en) 2024-05-22
US20230128114A1 (en) 2023-04-27
EP4125835A1 (en) 2023-02-08
JP2023521634A (ja) 2023-05-25

Similar Documents

Publication Publication Date Title
CO2019008986A2 (es) Derivados de tirosinamida como inhibidores de rho-quinasa
CO2020010342A2 (es) Composiciones de arni de 17 β -hidroxiesteroide deshidrogenasas tipo 13 (hsd17b13) y métodos de uso de las mismas
MX2022001337A (es) Uso de cannabidiol en el tratamiento del sindrome de dravet.
CL2012001298A1 (es) Compuestos derivados del acido carbomoil-metilamino acetico sustituido, inhibidores de nep; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de hipertension arterial, hipertension pulmonar, insuficiencia cardiaca, entre otras.
MX2021012639A (es) Pirrolopirimidinas como potenciadores de cftr.
CY1115708T1 (el) Τοπικες συνθεσεις για τη διατηρηση ή την ανακτηση της ακεραιοτητας των βλεννογονων
CL2011002787A1 (es) Compuestos derivados de 1-cianoetilheterociclilcarboxamida sustituidos, inhibidores de dipeptidilpeptidasa i (dppi) o catepsina c; composicion farmaceutica; combinacion faramceutica; y su uso en el tratamiento del asma, la enfermedad obstructiva cronica o la rinitis alergica.
MX2018005166A (es) Mezcla de tabaco.
BR112015006571A2 (pt) composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para a profilaxia ou tratamento de asma, doença pulmonar obstrutiva crônica e distúrbios respiratórios relacionados
CR9832A (es) Compuestos de pirimidina amida como inhibidores de pgds
UY30794A1 (es) Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinic0
CO6791573A2 (es) Sistema y métodos para el uso en línea del rastro social que afecta el rendimiento de los préstamos y la puntuación del crédito
MX2019006881A (es) Composicion farmaceutica que comprende derivados de glutarimida y uso de los mismos en el tratamiento de enfermedades eosinofilicas.
CL2008003301A1 (es) Compuestos derivados de 3,4-dihidropirazina-2-carboxamida, inhibidores de la elastasa de neutrofilos humanos; composiciones farmacéuticas; procesos de preparación de compuestos y composición farmacéutica; y uso en el tratamiento de síndrome de dificultad respiratoria de los adultos, fibrosis quística, cáncer, entre otras.
BR112013023380A2 (pt) processo para produzir um derivado de celulose particulado, método de aumento da fluidez ou da temperatura de início de dissolução de um derivado de celulose particulado, derivado de celulose particulado e forma de dosagem
NO341676B1 (no) Tetrahydro-pyrimidoazepiner som modulatorer av TRPVI
CL2014003286A1 (es) Composicion farmaceutica en forma de polvo seco que comprende abediterol; y su uso para el tratamiento de una enfermedad respiratoria seleccionada de asma y enfermedad pulmonar obstructiva cronica.
BR112012008276A2 (pt) instrumento para inspeção visual ou manutenção de turbinas
CL2013002542A1 (es) Uso de una composicion farmaceutica inhalable que contiene glicopirrolato o una sal del mismo para el tratamiento o profilaxis de taquicardia en pacientes con enfermedad pulmonar obstructiva cronica, asma, fibrosis quistica y enfermedades relacionadas de las vias aereas.
AR093569A1 (es) Tensioactivos pulmonares reconstituidos
BR112014007127A2 (pt) métodos para retardar o início ou diminuir a progressão de um ou mais sintomas, para retardar o início ou a progressão de um ou mais sintomas, para identificar um indivíduo em necessidade de terapia de manutenção de a1pi, e para identificar indivíduos com risco elevado para exacerbações pulmonares, uso de a1pi, aparelho e meio para a administração aerossolizada de a1pi para a inalação, e, kit
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
CL2008003495A1 (es) Compuestos derivados de pirazol; composicion farmaceutica, metodo de preparacion y; su uso para tratar una enfermedad mediada por 5-lo tal como asma, broncocontriccion, enfisema, enfermedades obstructivas o inflamatorias de las vias respiratorias, bronquitis, lesion pulmonar aguda, bronquiectasia, rinitis alergica, entre otras.
CL2008000973A1 (es) Compuestos derivados de 1-oxo-isoquinolina; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de enfermedades pulmonares obstructvas crónicas (epoc) y asma.
CL2010001421A1 (es) Uso de dronedarona en la preparacion de medicamentos utiles para la prevencion de fibrilacion o aleteo auricular persistentes.